文献速递真实世界研究与卫生经济流行病学与生物统计

使用β回归估计减重后HbA1c用于行为体重管理项目GLoW试验的经济评价:一项方法学研究

Estimation of HbA1c after weight loss using a beta-regression for an economic evaluation of a behavioural weight management programme from the GLoW trial: a methodological study.
PubMed 文献 · Lancet · 2023-01-01

GLoW试验纳入577名确诊2型糖尿病3年内的成人,比较混合效应回归估计的平均效应与β回归估计的异质性效应在12个月HbA1c分布拟合上的差异,并用SPHR糖尿病治疗模型评估终身NHS成本和QALYs。β回归法估计的增量净收益为每人736英镑,而平均效应法为584英镑。作者认为,当关键干预结局不服从正态分布时,应考虑替代回归设定方法,但该方法需进一步研究以确定其在不同情境下的适用性。

要点

  • β回归估计的异质性HbA1c变化比平均效应更好地再现了干预后HbA1c的偏态分布。
  • β回归法估计的增量净收益为每人736英镑,平均效应法为584英镑。
  • 作者认为,若关键干预结局非正态分布,经济评价中应考虑替代回归设定方法。

核心结论

  • 当关键干预结局不服从正态分布时,经济评价中应考虑替代回归设定方法。
  • 该替代方法需进一步研究以确定其在不同情境下评估成本效果时的适用性。

研究设计与样本

  • 方法学研究,基于GLoW试验数据,比较混合效应回归估计的平均效应与β回归估计的异质性效应。
  • GLoW试验纳入577名确诊2型糖尿病3年内的成人,从英格兰159个站点招募,招募时间为2018年7月20日至2018年7月22日。
  • 参与者平均年龄60岁,女性278例(53%),男性247例(47%),白人474例(91%)。
  • 使用SPHR糖尿病治疗模型评估终身NHS成本和QALYs,贴现率3.5%,采用英国前瞻性糖尿病研究结局模型2风险方程。
  • 增量净收益按每QALY 20000英镑估值,通过确定性分析计算。

主要发现

  • β回归估计的异质性HbA1c变化比平均效应更好地再现了干预后HbA1c的偏态分布(Kolmogorov-Smirnov检验p=0.02 vs p=0.0000007)。
  • β回归法估计的增量净收益为每人736英镑,平均效应法为每人584英镑。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该替代方法需进一步研究以确定其在不同情境下评估成本效果时的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In economic evaluations, average intervention effects are usually applied to a population. However, this fails to reflect the change in the distribution of HbA1c due to heterogeneous responses to weight loss. We aimed to investigate whether allowing heterogeneous treatment effects using a beta regression better represented the distribution of HbA1c after a weight-loss intervention, and how this affected cost effectiveness. METHODS: The Glucose Lowering through Weight Management (GLoW) trial evaluated the effectiveness of a diabetes education and weight-loss intervention against a standard diabetes education programme. Adults diagnosed with type 2 diabetes within 3 years were recruited from Clinical Commissioning Groups across 159 sites in England from July 20, 2018, to July 22, 2018. Ethics approval (18/ES/0048) and participant informed consent were obtained. Considering the between-treatment-arm difference in HbA1c after 12 months, we compared a mean-effect estimated from a mixed-effects regression to a heterogeneous effect estimated from a beta regression performed on 12-month HbA1c conditional on baseline HbA1c, gender, diabetes duration and intervention group. We used the School of Public Health Research (SPHR) Diabetes Treatment model to apply these treatment effects and evaluate the lifetime NHS costs and quality-adjusted life-years (QALYs), discounted at 3·5%. The microsimulation model estimated diabetes-related health outcomes using the UK Prospective Diabetes Study Outcomes Model 2 risk equations and risk factor trajectory equations, alongside estimating diabetes remission, osteoarthritis, and cancer. We calculated the incremental net benefit (INB) of the intervention using a £20 000 per QALY valuation, by deterministic analysis. The GLoW trial is registered with the ISRCTN Registry, ISRCTN18399564. FINDINGS: The trial recruited 577 participants (mean age 60 years; 278 [53%] female, 247 [47%] male; 474 [91%] white ethnic background). Applying heterogeneous HbA1c changes better reproduced the skewness in post-intervention HbA1c than applying a mean-effect (Kolmogorov-Smirnov test p=0·02 compared with p=0·0000007). The beta-regression method suggested the intervention was more cost-effective, estimating an INB of £736 per person, compared with £584 when applying the mean-effect. INTERPRETATION: Alternative regression specification methods should be considered when evaluating the cost-effectiveness of interventions if the key intervention outcomes are not normally distributed. However, this alternative method requires further investigation to conclude its appropriateness in evaluating cost-effectiveness in different contexts. FUNDING: National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (Reference Number RP-PG0216-20010).

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Pidd K, Breeze P, Pollard D, et al. Estimation of HbA1c after weight loss using a beta-regression for an economic evaluation of a behavioural weight management programme from the GLoW trial: a methodological study. Lancet. 2023. PMID: 37997120. doi:10.1016/S0140-6736(23)02156-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。